share_log

B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $191

Benzinga ·  Sep 24 00:04  · Ratings

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $175 to $191.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment